A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy

ersözlü, tolga; BILGILI, AHMET MERT

doi:10.26650/Tr-ENT.2022.1039303

A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy

AHMET MERT BILGILI, (Cyprus International University Health Sciences Faculty, Lefkosa, Northern Cyprus)

Tolga Ersözlü (Namık Kemal Üniversitesi, Tıp Fakültesi, Kulak Burun Boğaz Anabilim Dalı, Tekirdağ, Türkiye)

The Turkish Journal of Ear Nose and Throat

2 0

Yıl: 2022 Cilt: 32 Sayı: 2 Sayfa Aralığı: 37 - 42 Metin Dili: İngilizce DOI: 10.26650/Tr-ENT.2022.1039303 İndeks Tarihi: 15-08-2022

A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy

Öz:

Objective: Larynx cancer constitutes 2% of all cancers in adults with 96% of larynx malignancies being squamous cell carcinoma (SHC). Apoptosis is a cell death mechanism that is quite different from necrosis. It is also known as programmed cell death, physiological cell death, or cell suicide. Physiological mediators that activate programmed cell death (apoptosis) are Fas and Fas Ligand (FasL). Materials and Methods: In a thesis study conducted by our authors in 2004, we investigated the relationship of Fas-Fas ligand-mediated apoptosis with survival in laryngeal cancer, prognostic factors (age, localization, histological grade, tumor size, lymph, blood vessel invasion), stage, and inflammatory response of the tumor. In this study, we investigated the relationship between survival and death rates after 20 years and Fas-FasL. Results: When FAS was evaluated 20 years later, a statistically significant difference was found between mortality rates depending on stage (p=0.023; p<0.05). While the survival rate is higher in stage 1 cases, the rate of death is higher in stage 3 cases. No statistically significant difference was found between mortality rates according to stages for FAS Ligand 20 years later (p>0.05). Conclusion: In conclusion, we found that the Fas/Fas-L system was not associated with clinical parameters in laryngeal cancers in our short-term follow-up. However, when we repeated our follow-up 20 years later, we found that Fas system deficiency, although not in FAS Ligand, adversely affected survival in the long term in laryngeal cancer patients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73(8):2013-26.
3. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59(20):5356-64.
4. Chinnaiyan AM, Tepper CG, Seldin MF, O’Rourke K, Kischkel FC, Hellbardt S, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced
5. Hug H. Fas-mediated apoptosis in tumor formation and defense. Biol Chem 1997;378(12):1405-12.
6. Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 1997;33(11):1860-4.
7. Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999;28(2):82-7.
8. Wang J, Gao J, Li Y, Zhao X, Gao W, Peng L, Yan D, et al. Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Gene 2013;524(2):193-6.
9. Muraki Y, Yoshioka C, Tateishi A, Fukuda J, Haneji T, Kobayashi N. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1999;37(1):37-40.
10. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69(4):415-29.
11. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998;58(10):2057-62.
12. Jäckel MC, Mitteldorf C, Schweyer S, Füzesi L. Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma. Head Neck 2001;23(8):646-52.
13. Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, et al. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000;164(1):231-9.
14. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999;5(9):2464-9.
15. Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002;20(2):291-7.
16. Müllauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin’s lymphoma. Mod Pathol 1998;11(4):369-75.
17. Das SN, Khare P, Singh MK, Sharma SC. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma. Indian J Med Res 2011;134(1):54-60.
18. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA, et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab 1999;84(8):2924-32.
19. Ji X, Jiang C, Liu Y, Bu D, Xiao S. Fas ligand gene transfer effectively induces apoptosis in head and neck cancer cells. Acta Otolaryngol 2011;131(8):876-81.
20. Costa EFD, Lima TRP, Lopes-Aguiar L, Nogueira GAS, Visacri MB, Quintanilha JCF, et al. FAS and FASL variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients. Tumour Biol 2020;42(7):1010428320938494. doi: 10.1177/1010428320938494

APA	BILGILI A, ersözlü t (2022). A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. , 37 - 42. 10.26650/Tr-ENT.2022.1039303
Chicago	BILGILI AHMET MERT,ersözlü tolga A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. (2022): 37 - 42. 10.26650/Tr-ENT.2022.1039303
MLA	BILGILI AHMET MERT,ersözlü tolga A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. , 2022, ss.37 - 42. 10.26650/Tr-ENT.2022.1039303
AMA	BILGILI A,ersözlü t A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. . 2022; 37 - 42. 10.26650/Tr-ENT.2022.1039303
Vancouver	BILGILI A,ersözlü t A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. . 2022; 37 - 42. 10.26650/Tr-ENT.2022.1039303
IEEE	BILGILI A,ersözlü t "A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy." , ss.37 - 42, 2022. 10.26650/Tr-ENT.2022.1039303
ISNAD	BILGILI, AHMET MERT - ersözlü, tolga. "A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy". (2022), 37-42. https://doi.org/10.26650/Tr-ENT.2022.1039303

APA	BILGILI A, ersözlü t (2022). A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. The Turkish Journal of Ear Nose and Throat, 32(2), 37 - 42. 10.26650/Tr-ENT.2022.1039303
Chicago	BILGILI AHMET MERT,ersözlü tolga A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. The Turkish Journal of Ear Nose and Throat 32, no.2 (2022): 37 - 42. 10.26650/Tr-ENT.2022.1039303
MLA	BILGILI AHMET MERT,ersözlü tolga A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. The Turkish Journal of Ear Nose and Throat, vol.32, no.2, 2022, ss.37 - 42. 10.26650/Tr-ENT.2022.1039303
AMA	BILGILI A,ersözlü t A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. The Turkish Journal of Ear Nose and Throat. 2022; 32(2): 37 - 42. 10.26650/Tr-ENT.2022.1039303
Vancouver	BILGILI A,ersözlü t A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy. The Turkish Journal of Ear Nose and Throat. 2022; 32(2): 37 - 42. 10.26650/Tr-ENT.2022.1039303
IEEE	BILGILI A,ersözlü t "A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy." The Turkish Journal of Ear Nose and Throat, 32, ss.37 - 42, 2022. 10.26650/Tr-ENT.2022.1039303
ISNAD	BILGILI, AHMET MERT - ersözlü, tolga. "A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy". The Turkish Journal of Ear Nose and Throat 32/2 (2022), 37-42. https://doi.org/10.26650/Tr-ENT.2022.1039303